MOUNTAIN VIEW, Calif., Sept. 25, 2014 /PRNewswire/ -- Omnicell® Inc. today announced the commencement of the STOMPP (Study the Effect of a Hybrid Pharmacy Practice Model on Medication Adherence) clinical study. The evaluation is led by Dr. Sharrel Pinto, Division Head and Associate Professor in the Health Outcomes and Socioeconomic Sciences Division and Research Director of the Center for Pharmaceutical Care and Outcomes Research at The University of Toledo College of Pharmacy and Pharmaceutical Sciences.
It is estimated that poor medication adherence costs the U.S. health system more than $290B annually due to many factors, including preventable emergency room visits, hospital readmissions and the avoidable onset of advanced medical issues. STOMPP will evaluate whether community pharmacists' efforts to educate their patients and provide access to adherence packaging solutions result in improved adherence outcomes.
The primary endpoint of STOMPP, measured at one year, is to determine if the hybrid pharmacy practice model use of adherence packaging and/or medication therapy management has an impact on medication adherence. Study subjects will also be followed to assess clinical outcome measures, quality of life, and cost and utilization data. STOMPP will enroll up to 300 subjects with metabolic syndrome and Type II Diabetes.
The adherence packaging used in the study is provided by MTS, a global provider of adherence packaging solutions and a division of Omnicell. The MTS adherence packaging is designed to enhance the overall quality of care of individuals by reducing administration errors and improving appropriate medication utilization.
"Beyond the designed end points of this study, one early observation is the sheer number of individuals who are enthusiastic about being enrolled in a study of this kind," said Dr. Pinto. "Findings from my focus group study, presented earlier this year at the American Pharmacists Association, have provided early evidence that the adherence packs help in improving medication adherence and keeping patients healthy and out of the hospital. Individuals and their families are anxious for a solution that will help them take medications on time, as directed, and track their adherence after the fact. As a pharmacist, I share responsibility with prescribing physicians, caregivers, and patients themselves to all do our part in ensuring the patient's future health and wellness. We expect STOMPP will quantify what we've learned to date."
"We are pleased to support a leading researcher within an integrated delivery network environment where multiple patient populations require the upmost attention to ensure on-going levels of wellness," said Joe Lynch, Omnicell vice president, marketing - medication adherence. "Dr. Pinto's tireless research has shown that patients want to participate in improving their own lives. We are confident that when the final data are presented, this will be seen as the most comprehensive independent evaluation of how impactful adherence packaging can be in improving patient outcomes."
For additional perspective, on how pharmacists can contribute to better patient outcomes through improved medication adherence, please see researcher Sharrel Pinto, BSPharm, DMM, MS, PhD's recent publication about instituting an Adherence Pharmacy.
Since 1992, Omnicell (NASDAQ: OMCL) has been creating new efficiencies to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.
More than 3,000 customers worldwide have utilized Omnicell Automation and Analytics solutions to increase operational efficiency, reduce errors, deliver actionable intelligence and improve patient safety. Omnicell Medication Adherence solutions, including its MTS Medication Technologies brand, provide innovative medication adherence packaging solutions to help reduce costly hospital readmissions. In addition, these solutions enable approximately 6,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.
For more information about Omnicell, Inc. please visit www.omnicell.com.
OMCL - G
- All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the company's external website, omnicell.com.
- Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.
- All other brand or product names may be trademarks or registered trademarks of their respective companies.
Logo - http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a
SOURCE Omnicell, Inc.